Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia.

ABSTRACT:

Introduction

Chronic lymphocytic leukaemia, a common blood cancer in adults, particularly affects the elderly and is marked by the accumulation of B lymphocytes. While therapeutic options have expanded, the fludarabine, cyclophosphamide, and rituximab (FCR) regimen remains the standard first-line treatment for fit patients in the Brazilian public health system.

Aim

This systematic review aimed to assess the efficacy and safety of ibrutinib plus rituximab (IR) as a first-line therapy for chronic lymphocytic leukaemia.

Methods

Following PRISMA guidelines and registered in PROSPERO (CRD42023494868), searches were conducted in multiple databases in December 2023 to identify relevant randomized controlled trials comparing the IR and FCR regimens. Eligible studies reported

SUBMITTER: Nascimento AD 

PROVIDER: S-EPMC12769392 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature